★
KRYS
Krystal Biotech Inc · Biotechnology
FCF$237mC
Rev+25.1%A-
D/E0.01A
P/E39.2xC
PEG1.56C+
79Score
$302.681Y Target$348.08Near-term target
5Y Target$487.47Compound horizon
10Y Target$716.55Long-dated conviction
FCF$237mTTM · 03/26C
FCF $237m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+25.1%TTM YoYA-
Revenue +25.1% — strong growth, well above S&P median (~7%) · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.01totalA
D/E 0.01 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E39.2xC
P/E 39.2 — rich valuation; execution risk material
PEG1.56proxyC+
PEG 1.56 — modest premium; above fair value · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $8.9b. 5% off the 52-week high of $319.48. Revenue growing +25% — in hypergrowth territory.
Moat
Net margin 54% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 39x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 21.2x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Horizon
1-3 yr $348.08 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $487.47 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $716.55 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · KRYS
Shares to buy
6
Position size
$1,816
3.6% of portfolio
Stop price
$227.01
25% below $302.68
$ at risk
$500.00
1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.